A Phase 1 interventional study of Briquilimab and Placebo Comparator in Allergic Asthma, sponsored by Jasper Therapeutics, Inc.. Terminated at 6 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Jasper Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Study JSP-CP-012 is designed as a proof of concept, parallel-group, single dose, double blind, placebo-controlled study using an allergen challenge model. A single dose proof of concept approach at a dose level shown to be biologically active should inform the impact of briquilimab on allergic asthma as compared to placebo while minimizing exposure to participants, in a new indication.
4,841 studies on the registry are indexed under Asthma; 600 are open to participants now.
This study's enrollment of 17 is below the median of 78 across 3,341 interventional studies indexed under Asthma.
Browse Asthma studies →Jasper Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Placebo Comparator
Drug: Briquilimab
Subcutaneous Administration
Also known as: JSP191
Subcutaneous Administration
To evaluate the safety and tolerability of briquilimab in mild-to-moderate asthmatic participants
Incidence and/or severity of AEs, treatmentemergent adverse events (TEAEs), SAEs, AEIs, and AEs leading to discontinuation. Incidence of clinically significant abnormal laboratory values and vital signs.
Time frame: From signing the informed consent form (ICF) through end of trial (EOT) visit (up to 4.5 months)
To compare the effect of treatment with briquilimab vs placebo on the allergen-induced LAR
Allergen-induced LAR will be measured by maximum percentage fall in FEV1 during the period 3-7 hours after the allergen challenge and compared between briquilimab and placebo at week 6.
Time frame: 3-7 hours after allergen challenge between Briquilimab and Placebo at week 6
To compare the effect of treatment with briquilimab vs placebo on the allergen-induced LAR
Allergen-induced LAR will be measured by area under the FEV1 time-response curve \[AUC\] during the period 3-7 hours after the allergen challenge and compared between briquilimab and placebo at week 6.
Time frame: 3-7 hours after allergen challenge between Briquilimab and Placebo at week 6
To compare of the allergen-induced early asthmatic response (EAR) between briquilimab and placebo.
Allergen-induced EAR will be measured by maximum percentage fall in FEV1 during the period 0-2 hours after the allergen challenge and compared briquilimab and placebo at week 6.
Time frame: 0-2 hours after the allergen challenge and compared briquilimab and placebo at week 6
To compare of the allergen-induced early asthmatic response (EAR) between briquilimab and placebo.
Allergen-induced EAR will be measured by area under the FEV1 time-response curve \[AUC\] during the period 0-2 hours after the allergen challenge and compared briquilimab and placebo at week 6.
Time frame: 0-2 hours after the allergen challenge and compared briquilimab and placebo at week 6
Comparison of allergen-induced inflammatory mediators at 7h and 24h post allergen, between briquilimab and placebo
Changes from pre-allergen challenge sputum inflammatory mediators to 7 hours and 24 hours after the allergen challenge, compared between briquilimab and placebo at week 6.
Time frame: 7 hours and 24 hours after the allergen challenge, compared between briquilimab and placebo at week 6.
Comparison of the allergen-induced shift in AHR to methacholine at 24 hours after the allergen challenge, between briquilimab and placebo.
Changes from pre-allergen challenge AHR to 24 hours after the allergen challenge assessed by methacholine PD20, and compared between briquilimab and placebo at week 6.
Time frame: 24 hours after the allergen challenge compared between briquilimab and placebo at week 6.
Comparison of the allergen-induced changes in sputum leukocytes at 7h and 24h post allergen challenge, between the briquilimab and placebo.
Changes from pre-allergen challenge sputum leukocytes to 7 hours and 24 hours after the allergen challenge, compared between briquilimab and placebo at week 6.
Time frame: 7 hours and 24 hours after the allergen challenge, compared between briquilimab at week 6. and placebo.
Plan to share: No
No publications or documents are linked to this record.
This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Briquilimab
Jasper Therapeutics, Inc.